RxDoctor Payments Data

Shant Tomassian, MD

Family Medicine · Glendora, CANPI 1215594692

Payments from drug & device makers

$1,577in general payments, 2019–2025

Across 64 payments — averaging $24.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kowa Pharmaceuticals America, Inc.$191
  • Stryker$161
  • Esperion Therapeutics, Inc.$141
  • Boehringer Ingelheim$126
  • Gilead$121
  • Idorsia Pharmaceuticals US Inc$118
  • plus $720 from 17 others

What the payments were for

  • Food & beverage$1,577100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,577 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$40,932
Medicare patients
44
Services billed
348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate88$14,901
GemtesaVibegron103$12,836
EliquisApixaban53$10,916
XareltoRivaroxaban50$10,405
JardianceEmpagliflozin23$8,866
FarxigaDapagliflozin Propanediol43$6,278
Arnuity ElliptaFluticasone Furoate22$4,920
Potassium Chloride239$4,036
BreynaBudesonide/Formoterol Fumarate11$2,778
MyrbetriqMirabegron24$2,733
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc24$2,389
Lidocaine17$1,807
Atorvastatin Calcium419$1,717
Amiodarone Hcl62$1,588
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$1,424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$69$12,836103 claims
Boehringer IngelheimJardiance$126$8,86623 claims
AstraZenecaFarxiga$13$6,27843 claims
GSKArnuity Ellipta$57$4,92022 claims
Kowa Pharmaceuticals America, Inc.Livalo$191$92253 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Glendora

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →